<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Jan. 29, 2019 (HealthDay News) — Treating systolic blood pressure (BP) to a goal of less than 120 mm Hg rather than 140 mm Hg does not result in a significant reduction in the risk for probable dementia, according to a study published online Jan. 28 in the Journal of the American Medical Association<\/i>.<\/p>\n
Jeff D. Williamson, M.D., M.H.S., from the Wake Forest School of Medicine in Winston-Salem, North Carolina, and colleagues randomly assigned adults aged 50 years or older with hypertension to a systolic BP goal of <120 mm Hg (4,678 participants) or <140 mm Hg (4,683 participants).<\/p>\n
The trial was stopped early for benefit on its primary outcome (a composite of cardiovascular events) and all-cause mortality. The researchers found that adjudicated probable dementia occurred in 149 and 176 participants in the intensive and standard treatment groups, respectively, during a median follow-up of 5.11 years (7.2 versus 8.6 cases per 1,000 person-years; hazard ratio, 0.83; 95 percent confidence interval, 0.67 to 1.04). With intensive BP control, significant reductions were seen in the risk for mild cognitive impairment (14.6 versus 18.3 cases per 1,000 person-years; hazard ratio, 0.81; 95 percent confidence interval, 0.69 to 0.95) and in the combined rate of mild cognitive impairment and probable dementia (20.2 versus 24.1 cases per 1,000 person-years; hazard ratio, 0.85; 95 percent confidence interval, 0.74 to 0.97).<\/p>\n
“These results importantly show that intensive BP control did not result in harm to cognition,” the authors write. “Moreover, there is some indication that intensive BP control may be beneficial.”<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Takeda Pharmaceuticals, which provided study medications.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n